TriSalus Life Sciences, Inc. (TLSI) Stock

TriSalus Life Sciences, Inc. operates as a pioneering medical technology company specializing in the research, development, and commercialization of innovative drug delivery systems and immune-oncology therapies. Focused primarily on addressing liver and pancreatic cancers, TriSalus offers advanced Pressure Enabled Drug Delivery infusion technologies. These include the TriNav infusion system, crucial for transarterial radioembolization and chemoembolization procedures in patients with liver cancer and metastases. Additionally, the company is advancing the Pancreatic Retrograde Venous Infusion device, currently in Phase 1 clinical trials, designed specifically for treating locally advanced pancreatic cancer.

Founded in 2009 and headquartered in Westminster, Colorado, TriSalus Life Sciences is dedicated to pushing the boundaries of therapeutic innovation. Among its notable developments is nelitolimod, an investigational immunotherapeutic currently undergoing Phase 1 clinical trials. Nelitolimod shows promise for treating a range of conditions, including uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. This underscores TriSalus' commitment to advancing novel treatments that offer new hope to patients facing complex and challenging cancers.

TriSalus Life Sciences serves a diverse array of healthcare professionals, including interventional radiologists, IR technicians, medical oncologists, and nursing support teams, facilitated through a dedicated network of sales representatives and managers. By integrating cutting-edge technologies with rigorous clinical research, TriSalus strives to improve patient outcomes and redefine standards of care in oncology treatment worldwide.